Background: Mortality prediction models are applied in the intensive care unit (ICU) to stratify patients into different risk categories and to facilitate benchmarking. To ensure that the correct prediction models are applied for these purposes, the best performing models must be identified. As a first step, we aimed to establish a systematic review of mortality prediction models in critically ill patients.
| INTRODUC TI ON
Outcome prediction models, severity scales and risk scores are prognostic tools to estimate the probability for a pre-specified outcome. 1 These prognostic tools use variables (eg about the severity of illness) to predict outcome, often mortality, in a specific patient population such as the critically ill. In the intensive care unit (ICU), mortality prediction models may be applied to stratify patients in different risk categories and to facilitate benchmarking using standardized mortality rates. An accurate mortality prediction model provides a stratification of the risk of an outcome at a population level. These models generally provide a numerical estimate of that risk based on estimates from previous populations. 2 Per definition, all mortality prediction models are best suited for use at a population level and not for individual prognostication, as uncertainty for individual patients remains high. 3, 4 Several models are widely known and broadly applied such as the Acute Physiology and Chronic Health Evaluation (APACHE) I-IV, the Mortality Prediction Model (MPM) and the Simplified Acute Physiology Score (SAPS) I-III, 5 whereas others like the Intensive Care National Audit & Research Centre (ICNARC) are used solely in one country. 6 Previous literature has only reviewed commonly used models, models with different outcome than mortality or disease-or organ-specific prognostic models. [3] [4] [5] 7, 8 To the best of our knowledge, no study has systematically assessed which mortality prediction models have been developed and validated for broad cohorts of adult critically ill patients.
| Rationale and objective
The objective of this study was to provide an overview of available mortality prediction models in adult critically ill patients as a stepup towards future head-to-head comparison of model performance through systematic external validation.
| ME THODS

| Protocol and registration
This scoping review was performed following our protocol (Appendix S1) and was reported in accordance with the PRISMA-ScR checklist. 9 Notably, we aimed to publish the protocol on PROSPERO, but during the process it showed that PROSPERO currently does not accept registrations for scoping reviews, literature reviews or mapping reviews.
| Search strategy
We conducted a systematic search of MEDLINE, EMBASE, Web of Science and The Cochrane Central Register of Controlled Trials (CENTRAL) to identify relevant ICU mortality prediction models (Appendix S1). Mortality was chosen as the outcome of interest, as prediction models were originally developed to identify patients with high mortality risk. For all databases, except the CENTRAL database, the search period encompassed a period starting from the 1st January 2008 to the 21st April 2019. We used snowballing, that is, searching references and related articles, to identify additional prediction models that were published before 2008.
One author ran the search, after which the screening of records and data extraction were performed in duplicate. All records were screened based on title and/or abstract. Papers clearly irrelevant to the purpose were excluded. The remaining articles were screened for eligibility. Consulting a third opinion solved disagreements. More detailed information is presented in the protocol (Appendix S1).
| Eligibility criteria
To be considered eligible, mortality prediction models had to meet the following criteria: (a) originally developed specifically for use in adult critically ill patients as defined by the included studies, (b) representing Calibration was not assessed in 11 models (26%). Overall performance was assessed in the Brier score (19%) and the Nagelkerke's R 2 (4.7%).
Conclusions:
Mortality prediction models have varying methodology, and validation and performance of individual models differ. External validation by the original researchers is often lacking and head-to-head comparisons are urgently needed to identify the best performing mortality prediction models for guiding clinical care and research in different settings and populations.
Editorial Comment
In this review, mortality prediction models in intensive care have been identified. Characteristics and performance of 43 individual models are summarized according to documentation in the original publications so that validation and predictive performances can be compared. broad groups of ICU patients (with large diversity of admission diagnoses, eg non-diabetic patients, medical admissions, surgical admissions, etc), (c) availability of the original article in English and (d) mortality at any time as (primary or secondary) outcome of interest.
Prediction models were excluded (a) when developed for low-or middle-income countries, as characteristics of ICU patients in these countries often substantially differ from those in high-income countries and, epidemiological data from low-income countries have been frequently unavailable, 10, 11 (b) when developed as a digital model or derived from a machine-learning algorithm, since code and data availability are not requirements in all journals. Since our utmost goal is to make a head-to-head comparison of available mortality prediction models using an independent external validation cohort, the code or data necessary to retrieve the underlying prediction model formula are required to reproduce the prediction models. (c) When the development of multiple customized prediction models was described in one article, but no final model was proposed, the prediction models were excluded. Finally, (d) we excluded prediction models specifically developed for subgroups of intensive care patients such as those with sepsis, trauma, cardiac and neurological patients. Studies not specifying inclusion of these subgroups within a wider, general ICU population were considered to be eligible. Prediction models developed in a medical or surgical ICU were included.
| Data extraction
If multiple mortality outcomes (eg at different time points) were used, we used the primary outcome in the original publication (or the first mortality outcome if the primary outcome was not mortality) to describe the performance of the prediction model. Details on the development process of the mortality prediction models included were shown, as well as the number of variables included in the prediction models, mortality rate in each development setting and method of handling of missing data. To give an overview of the performance of all mortality prediction models, for example, values from discrimination, calibration and overall performances Citations of original publications were screened for internal and/ or external validation articles and shown as being present (+) or absent (−). A list of variables sought for in the identified articles can be found in Appendix S1.
| RE SULTS
The selection of sources of evidence can be found in the flowchart ( Figure 1 ). Articles evidently developed for specific groups of patients (ie sepsis, trauma, cardiac, neurological patients) were excluded based on the title and/or abstract. Evaluating 99 full-text articles for eligibility resulted in exclusion of another 39 articles, leaving 60 articles that were screened for original publications.
Eventually, 43 relevant mortality prediction models reported in 38 publications were extracted and included in the final analysis.
| Characteristics of the included mortality prediction models
Characteristics of the mortality prediction models and underlying derivation cohorts are presented in Table 1 . In all, 19 mortality prediction models (44%) were developed using prospectively collected data specifically gathered for the development of the prediction model, 6, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] whereas 24 (56%) were developed using either retrospective data [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] or prospective data previously collected for other purposes. [45] [46] [47] [48] [49] The start of data collection for the development cohorts spanned 36 years (1979-2015) , and the duration of the cohort studies varying from 2 months up to 10 years for each cohort. Two mortality prediction models (4.7%) did not report the timespan during which their development cohort was assembled. 22, 33 In all, 31 mortality prediction models (74%) were developed in a single country, 14, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] 29, 31, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] 47, 49 six (14%) in neighbouring countries (two or more) 6, 13, 28, 30, 32, 46 and five (12%) were developed in multiple countries worldwide. [15] [16] [17] 48 The number of patients included in the development databases ranged from 232 to 731 611 patients with a median of 4,895 (IQR 528-35 878). The minimum age at which patients were included was 15 years (2.3%). 35 In all, 11 mortality prediction models (26%) did not specify age. 6, 13, 23, 25, 29, 31, 36, 38, 42, 46 The number of variables included in the mortality prediction models varied from 5 up to 5695, with a median of 16 (IQR 9-24).
| Outcome measures
The timing of mortality outcome varied between the studies. Hospital mortality was the most frequently used primary outcome in 29 (67%) mortality prediction models. 6, [13] [14] [15] [16] [17] [18] [19] 21, 22, 24, 27, 28, [30] [31] [32] [33] 35, 36, 38, [41] [42] [43] 45, 46 Other primary outcome variables were ICU mortality (7%), 23, 26, 34 28-day mortality (4.7%), 39, 44 90-day mortality (4.7%), 48, 49 3-to 28-day mortality (4.7%), 40 30-day mortality (2.3%), 47 180-day mortality (2.3%), 20 6-month mortality (2.3%), 25 15-year mortality (2.3%), 37 and 6-and 12-month mortality (2.3%). 29 Secondary outcomes were 1-month mortality after ICU admission (4.7%), 24, 31 hospital mortality (4.7%), 29, 34 ICU mortality (2.3%), 45 3-month mortality after ICU admission (2.3%), 31 6-month mortality after ICU admission (2.3%), 31 9-month mortality (2.3%), 47 1-year mortality (2.3%) 45 and length of stay (2.3%). 24 Of the 43, 37 mortality prediction models (86%) did not prognosticate any secondary outcome. 6, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [25] [26] [27] [28] 30, 32, 33, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] 46, 48, 49 Hospital mortality rates of the development cohorts varied from 6.9% to 48% and were not reported for nine mortality prediction models (21%). 6, 15, 18, 29, 33, 40, 42 For 21 mortality prediction models (49% of 43), data were collected within the first 24 hours after patient admission to the ICU. 6, 13, 14, [17] [18] [19] 24, 26, 27, 30, 31, 34, 38, 39, 42, 44, [47] [48] [49] For 11 prediction models (26%), data on ICU admission were collected, 16, 23, 25, 28, 32, 35, 36, 41, 43, 45, 46 whereas for the remaining prediction models data timing varied from 24 days before admission up to 5 days after patient admission to the ICU.
Handling of missing data was not reported in 11 mortality prediction models (26%), 23, 25, 26, 31, 33, 38, 39, 41, 45, 46, 49 20 prediction models (47% of 43) excluded records with missing data, 6, 14, 16, 19, 21, 24, 27, 28, 30, 32, 34, 40, [42] [43] [44] six prediction models (14%) imputed values with normal or mean values 15, 17, 18, 20, 22, 29 and four prediction models (9.3%) reported no missing data. 13, [35] [36] [37] The remaining two prediction models (4.7%) excluded patients when more than a certain percentage of the data was missing (>5% or >25%). 47, 48 
| Discrimination, calibration and overall performance measures
Discrimination, calibration and overall performance measures are presented in Table 2 . Of the 43 mortality prediction models, 15 (35%) were only internally validated, 23,26,28-31,33,38-41,44,46,48 13 (30%) only externally, 16, [19] [20] [21] 25, 35, 36, 42, 43, 47 10 (23%) were both internally and externally validated, 6, [13] [14] [15] 17, 18, 22, 32, 34, 37 and 5 prediction models (12%) were not validated at all. 24, 27, 45, 49 In all, 15 prediction models (35%) included a description of an external validation in their original publication. 13, 16, [20] [21] [22] 25, [34] [35] [36] 42, 43, 47 Discrimination was expressed as the AUROC in 42 of the 43 mortality prediction models original publications (98%). Only the APACHE II model did not report an AUROC value in the original publication. 19 In the development cohorts, the lowest discrimination was AUROC 0.72 (95% CI 0.71-0.74), 48 and the highest AUROC 0.91 (95% CI not specified). 30 In the validation cohorts, the lowest AUROC was 0.58 (95% CI not specified), 44 and intensive care therapy; RDW, red cell distribution width; SAPS, simplified acute physiology score; SMS-ICU, simplified mortality score for the intensive care unit; SQ, surprise question; SUPPORT, study to understand prognoses and preferences for outcomes and risks of treatments; TRIOS, three-day recalibrating ICU outcomes.
a When (parts of) other mortality prediction models were used as variables in a mortality prediction model (eg the Charlson Comorbidity Index and APACHE III as variable in the Mortality Prognostic Model), variables included in these specific mortality prediction models were also taken into account.
b
Estimated based on information in original publication. TA B L E 2 (Continued) models (60%). [14] [15] [16] [17] 21, 22, [24] [25] [26] 28, 30, [32] [33] [34] [35] [36] [38] [39] [40] [41] 43, 46, 48 Calibration plot was expressed for 12 prediction models (28%), 13, 15, 20, 24, 28, 30, 31, 33, 35, 37, 43, 48 and two prediction models (4.7%) presented the calibration slope value. 30, 48 Finally, one prediction model (2.3%) used the likelihood ratio test chi-squared value, 23 and one prediction model (2.3%) used the Quasi likelihood under the Independence Criterion. 45 In 11 prediction models (26%), calibration was not assessed. 6, 18, 19, 27, 29, 42, 44, 47, 49 Overall performance was expressed as the Brier score in eight mortality prediction models (19%), 6, 13, [28] [29] [30] [31] 34, 41 and as Nagelkerke's R 2 in two prediction models (4.7%). 37, 48 
TA B L E 1 (Continued)
TA B L E 2 Performance of the 43 mortality prediction models
| D ISCUSS I ON
| Main findings
In this scoping review, we presented a contemporary overview of 43 mortality prediction models used in adult ICU patients in highincome countries. We found varying methodology, and the validation and performance of individual prediction models differ. Only 23 mortality prediction models of the 43 (53%) were externally validated. This overview provides a basis for head-to-head comparison of existing mortality prediction models through systematic external validation, with the ultimate goal to identify the most suitable prediction model for a certain cohort of patients.
| Summary of evidence
In previous literature, the maximum number of ICU mortality prediction models reviewed was 12, 7 which is considerably less than the 43 prediction models identified by this review. Where we included all developed prediction models specifically designed to assess mortality, other reviews regarding ICU mortality prediction models focused mainly on commonly used models like the APACHE, SAPS and MPM, [3] [4] [5] or identified models with different outcome than mortality (eg organ dysfunction) or disease-or organ-specific prognostic models. 4, 5, 7, 8 Model performance is affected by the choice of outcome. 31, 50 Most mortality prediction models used hospital mortality as outcome measure. 6, [13] [14] [15] [16] [17] [18] [19] 21, 22, 24, 27, 28, [30] [31] [32] [33] 35, 36, 38, [41] [42] [43] 45, 46 In general, longer fixed-time outcome measures used in some models 20, 24, 25, 29, 31, 37, 39, 40, 44, 45, [47] [48] [49] are currently recommended. 51 To elaborate, hospital mortality is dependent on discharge practices and availability of post-ICU care, and is therefore a subjective measure. Furthermore, critical illness affects patients after hospital discharge.
The time span during which the mortality prediction models gathered their data varied from short (eg upon ICU admission or during the first initial hour of admission to the ICU) to long (eg during the first 24 hours of admission). Concerning complexity (time consumption) and missing data problems, it may be better in some situations to use a simpler model with less missing data than a more complex model built from a dataset with more missing data which achieves a slightly better performance. 52 Longer collection periods may lead to more complete data, as incompleteness is often substantial for biochemical variables for patients with short-duration admissions (ie less than 24 hours). However, sampling rate affects predictions. 53 This limitation is considered less important in models with shorter data collection. Similarly, the treatments administered during the first 24 hours in the ICU obviously also affect predictions.
| Comparison of performance
We reported the performance of mortality prediction models in terms of discrimination, calibration and overall performance values.
Direct comparison of prediction models predictive performances is not possible, as the development cohorts differed substantially from one another. As a consequence, prediction models cannot be considered interchangeable. Comparisons that are not done head-to-head in external samples independent of all models developed are at high risk of being misleading and may lead to inappropriate conclusions and resource use. 12 Of 43, 26 (60%) mortality prediction models used the HL goodness-of-fit test for calibration. [14] [15] [16] [17] 21, 22, [24] [25] [26] 28, 30, [32] [33] [34] [35] [36] [38] [39] [40] [41] 43, 46, 48 The HL test is commonly used, despite being frequently non-significant for small data cohorts and nearly always significant for large data cohorts. [54] [55] [56] [57] When only the HL test is reported without any calibration plot or table comparing predicted and observed outcome frequencies, inadequate information regarding calibration is provided. 1
Many ICU mortality prediction models are available and comparatively assessing their performance is a crucial task. 4 In all, 25 articles compared the performance of the new model with existing models but used the same cohort of patients that was used in the development of the 'novel' model. 6, 13, 14, [16] [17] [18] 20, 22, 24, [26] [27] [28] [29] [30] 32, 34, [40] [41] [42] [43] [44] [45] [46] [47] 49 This methodology is inherently biased in favor of the 'novel' model. 54, 57 Comparisons between prediction models should therefore only be executed in independent external validation samples not used to develop any of the models.
| Machine-learning algorithms
Mortality prediction models developed as an electronic model or derived from a machine-learning algorithm such as AutoTriage 58
were excluded in our manuscript since code and data availability are not requirements in all journals and this is necessary to reproduce the specific prediction model. However, code availability appears to be a rising trend. 59 Machine-learning-based prediction models seem to achieve increasingly higher accuracies and are becoming more dynamic, 60 although they still have to include a sufficiently large development and validation cohort to adequately assess performance and the risk of overfitting. However, a recent systematic review concluded that machine learning did not have superior performance over logistic regression for clinical prediction models. 61 The association between mortality and variables may have changed since the original mortality prediction models were developed, for example, as a result of advancements in diagnostics and therapeutics. 62 Mortality alone however is rarely the only outcome measure for interventional studies in ICU patients, and many trials, especially in sepsis,
include an organ dysfunction score as part of ongoing patient assessment so that effects on morbidity can also be evaluated. 3 Misuse of mortality prediction models can lead to inappropriate use of resources and potentially even mismanagement of patient care due to incorrect stratification. 57 Awareness of the differences in model design, the variance of predictions across different ICU settings and the effect of heterogeneity in populations are of utmost importance.
| Limitations
Some limitations of this study need to be addressed. First, having restricted our search to the period from 2008, relevant mortality prediction models might have been overlooked. Even though some of the most widely used mortality prediction models precede the screening period, we identified 16 prediction models that were published before 2008, but optimally searches have no time limit. 63 Second, we only included mortality prediction models originally developed for use in the ICU. Mortality prediction models not originally developed for mortality prediction in the ICU could still be valuable clinically. Third, in some original publications, it was unclear whether the presented discrimination, calibration and/or overall performance values were derived from the development cohort or from the validation dataset. We aimed to clarify these, but certain values might reflect another dataset from the original publication. Fourth, we only provided a systematic overview of all developed mortality prediction models in adult critically ill patients. We did not perform a systematic review of every retrieved model complete with all consecutive internal and external validations, as results from different external validations in different cohorts are not directly comparable due to differences in populations, case-mix and settings. We restricted the scope of this review to only identify whether internal or external validation had been performed as a measure of thoroughness of development of the identified models. For this reason, only screening of citations of the original articles was done to identify internal and/ or external validation articles. Therefore, we should address that our assessment on mortality prediction models not being internally and/or externally validated might be incomplete if validation in different publications was missed. A systematic search specifically designed for retrieving validation papers is advised when systematically reviewing the internal and external validations of mortality prediction models. 64 
| Unanswered research questions
Although we retrieved many developed mortality prediction models that can be used as a step towards future head-to-head comparison, with the results of this scoping review it is not possible to make a recommendation on what mortality prediction models to use and it was not our intention to do so. External validation involving direct head-to-head comparisons in independent cohorts is needed to unravel the comparable performance of individual models. Although we provide a systematic overview of mortality prediction models and describe whether these were internally and/or externally validated, it was not desirable to give an overview of all external validations of the prediction models since this would require a specific search strategy for each model. Moreover, we would have liked to assess risk of bias using the recently developed PROBAST score. 1 However, this was not feasible because of the number of prediction models.
| FUTURE PER S PEC TIVE S
To identify the most suitable mortality prediction model for a certain patient cohort, ideally a head-to-head comparison of available models should be performed through systematic external validation using prospectively obtained datasets and appropriate statistical methods. The eventual aim will be to use this review to identify, update and implement the best performing mortality prediction models in daily practice. We are in the process of validating the found prediction models in independent contemporary cohorts to provide external validation of these models. Second, the process should be performed in different cohorts as heterogeneity of ICU patients exists on multiple levels, that is, patient level, hospital level, region and country level. 65 The best mortality prediction model in one setting is not necessarily the best performing prediction model in another setting. Third, it is worth mentioning that ICU patients have reduced long-term survival and impaired quality of life after ICU discharge compared to the general population. 66 Future research should also look at determinants of poor outcomes in ICU survivors to help guide long-term follow-up. 67 
| CON CLUS IONS
In this review, 43 mortality prediction models have been studied.
The validation and performance of individual prediction models
